CommercialCoverageMedium impact
08.00.90u, Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
IBX has updated their policy for Paclitaxel Protein-Bound Particles (Abraxane) injectable suspension. This is a commercial plan policy update for this oncology medication used in cancer treatment.
Action Required
By October 1, 2025: Review the full policy details at the provided URL to understand specific coverage changes for Paclitaxel Protein-Bound Particles (Abraxane). Billing team should verify current prior authorization requirements and coverage criteria for this oncology medication with IBX commercial plans.